Since over 60% of all CRC patients harbor TP53 mutations, we reasoned that p53-deficient CRC cells can still efficiently benefit from dual HSF1-HSP90 inhibition by direct CDK4/6 inhibition. The gene discussed is TP53; the disease is colorectal carcinoma.